Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $2.54 billion. The Firm is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. It currently has negative earnings. The Company’s clinical-stage pipeline consists of two product categories: biologics , and small-molecule substrate replacement therapies.
Analysts expect Macatawa Bank Corporation (NASDAQ:MCBC) to report $0.00 EPS on April, 27. The stock decreased 0.52% or $0.05 during the last trading session, reaching $9.58. About 58,006 shares traded or 20.31% up from the average. Macatawa Bank Corporation (NASDAQ:MCBC) has risen 19.78% since September 12, 2016 and is uptrending. It has outperformed by 11.29% the S&P500.
Investors sentiment increased to 1.84 in 2016 Q4. Its up 1.05, from 0.79 in 2016Q3. It increased, as 2 investors sold Macatawa Bank Corporation shares while 17 reduced holdings. 13 funds opened positions while 22 raised stakes. 8.66 million shares or 7.28% more from 8.07 million shares in 2016Q3 were reported. Vanguard Gp Inc stated it has 937,434 shares. First Trust Advsrs Ltd Partnership owns 0% invested in Macatawa Bank Corporation (NASDAQ:MCBC) for 29,287 shares. Raymond James & Associates reported 14,641 shares. Plante Moran Financial Advsrs Llc stated it has 24,815 shares or 0.16% of all its holdings. Banc Funds Com, Illinois-based fund reported 788,293 shares. Goldman Sachs Gru invested in 0% or 19,655 shares. State Common Retirement Fund reported 4,200 shares stake. Fifth Third Bank & Trust has invested 0% in Macatawa Bank Corporation (NASDAQ:MCBC). Millennium Management Limited Liability reported 0% stake. Morgan Stanley owns 173,625 shares or 0% of their US portfolio. Arcadia Mngmt Mi invested in 0.01% or 2,000 shares. Federated Investors Pa stated it has 0% in Macatawa Bank Corporation (NASDAQ:MCBC). Royal Financial Bank Of Canada holds 0% in Macatawa Bank Corporation (NASDAQ:MCBC) or 1,827 shares. Wells Fargo Mn owns 19,214 shares. Stifel Finance Corporation reported 19,353 shares.
Macatawa Bank Corporation is a bank holding company. The company has market cap of $325.15 million. The Company, through its subsidiary, Macatawa Bank , offers a range of commercial and personal banking services, including checking, savings and certificates of deposit accounts, cash management, safe deposit boxes, trust services and commercial, mortgage and consumer loans. It has a 20.38 P/E ratio. The Bank is a Michigan chartered bank with depository accounts insured by the Federal Deposit Insurance Corporation.
The stock increased 1.35% or $0.81 during the last trading session, reaching $60.89. About 4.40M shares traded or 657.61% up from the average. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) has declined 15.84% since September 12, 2016 and is downtrending. It has underperformed by 24.33% the S&P500.
Iguana Healthcare Management Llc holds 6.72% of its portfolio in Ultragenyx Pharmaceutical Inc for 160,000 shares. Weatherbie Capital Llc owns 168,915 shares or 1.49% of their US portfolio. Moreover, Columbia Wanger Asset Management Llc has 1.16% invested in the company for 1.18 million shares. The Massachusetts-based Cormorant Asset Management Llc has invested 1.05% in the stock. Emerald Advisers Inc Pa, a Pennsylvania-based fund reported 337,629 shares.
Analysts await Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to report earnings on May, 8. They expect $-1.73 earnings per share, down 28.15% or $0.38 from last year’s $-1.35 per share. After $-1.75 actual earnings per share reported by Ultragenyx Pharmaceutical Inc for the previous quarter, Wall Street now forecasts -1.14% EPS growth.
Ratings analysis reveals 79% of Ultragenyx Pharmaceutical Inc’s analysts are positive. Out of 14 Wall Street analysts rating Ultragenyx Pharmaceutical Inc, 11 give it “Buy”, 1 “Sell” rating, while 2 recommend “Hold”. The lowest target is $66 while the high is $126. The stock’s average target of $101.62 is 66.89% above today’s ($60.89) share price. RARE was included in 24 notes of analysts from July 27, 2015. As per Thursday, January 21, the company rating was initiated by Credit Suisse. Raymond James initiated the stock with “Outperform” rating in Tuesday, September 1 report. The rating was initiated by H.C. Wainwright on Tuesday, February 9 with “Buy”. The firm earned “Buy” rating on Tuesday, June 28 by Bank of America. The rating was downgraded by PiperJaffray to “Neutral” on Thursday, March 23. On Tuesday, December 1 the stock rating was initiated by Stifel Nicolaus with “Buy”. The firm earned “Neutral” rating on Tuesday, January 12 by Citigroup. The firm earned “Outperform” rating on Tuesday, May 10 by Wedbush. JMP Securities maintained the stock with “Market Outperform” rating in Wednesday, June 8 report. The stock of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) has “Buy” rating given on Monday, July 13 by SunTrust.
